ASH Meeting on Hematologic Malignancies

ASH Meeting on Hematologic Malignancies

Coverage of ASH’s newest clinical meeting, featuring top experts in hematologic malignancies discussing the latest developments in clinical care and answering challenging patient care questions

You Make the Call

From ASH Meeting on Hematologic Malignancies: How would you treat relapsed/refractory myeloma after transplant?

During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
You Make the Call

From ASH Meeting on Hematologic Malignancies: What are the approved options for relapsed marginal...

During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
You Make the Call

From ASH Meeting on Hematologic Malignancies: How would you treat this patient with high-grade...

During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
You Make the Call

From ASH Meeting on Hematologic Malignancies: Treating Patients With AML With Mutations and Minimal...

During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
You Make the Call

From ASH Meeting on Hematologic Malignancies: Treating “Problematic” Cases of Polycythemia Vera

During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
You Make the Call

From ASH Meeting on Hematologic Malignancies: Treating a Young Patient With Newly Diagnosed ALL

During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
You Make the Call

From ASH Meeting on Hematologic Malignancies: What is the prognosis for symptomatic, bulky FL...

During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
You Make the Call

From ASH Meeting on Hematologic Malignancies: How would you use molecular diagnostic tests to...

During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
You Make the Call

From ASH Meeting on Hematologic Malignancies: How would you treat MDS that has not...

During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...

Studies Examine Link Between Ibrutinib and Atrial Fibrillation in Patients With Leukemia and Lymphoma

Though drug ibrutinib has been linked to the development of atrial fibrillation (AF) and atrial flutter (AFl), with an observed incidence of AF among...
Advertisement

Current Issue

September 2019 Volume 5 Issue 11

September 2019, Volume 5, Issue 11

This issue explores politics in the exam room, demystifies proteomic analysis in hematology, and more.